•  
  •  
 

Abstract

BACKGROUND: Hodgkin’s lymphoma is one of most curable lymphoid malignancy. Here we conducted in this study the outcome of frontline therapy in adult Hodgkin’s lymphoma patients. AIM OF STUDY:   1. To evaluate   the results of first line treatment with ABVD chemotherapy protocol in patients with Hodgkin’s lymphoma in this study. 2. To find predictors associated with poor outcome of   first line treatment with ABVD chemotherapy protocol in patients with Hodgkin’s lymphoma in this study. METHODS:   This  is  a    retrospective and prospective study  in which  information  was gathered from Baghdad  hematology  center involving 50  patients  who  were  diagnosed  with Hodgkin’s lymphoma   from 1/1/ 2017  until  mid of  2019 and treated with frontline therapy, ABVD chemotherapy protocol. RESULTS:   The mean age of diagnosis was 29.6 ±12.12 year.  Nodular sclerosis   was the predominant subtypes constituted   (62%) of patients.  Advanced stage disease involved 86% of patients.  At  interim  evaluation by imaging studying including either ultrasound and CT scan or Pet scan according to availability ,  complete  remission, partial  remission and   progressive  disease involving    58% , 26%  and  16% of patients respectively. Two years progression free survival was 68.95%. There was a strong correlation between lymphocytopenia and progression free survival.  In  this  study,  univariate  analysis  showed  that  initial    lymphocytopenia was poorly associated with chance of achieving complete  remission    at  end  of treatment. CONCLUSION: The  outcome  of  ABVD  in  this  study  shows    lymphocytopenia was poorly associated with complete  remission    at  end  of treatment of patients.    

DOI

10.52573/ipmj.2021.175761

Download

Share

COinS